post-COVID-19 disorder

Summary

post-COVID-19 disorder (MONDO:0100320) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• ClinVar variants: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	post-COVID-19 disorder
Mondo ID	MONDO:0100320
Is cancer (heuristic)	no

Data availability: 1 ClinVar variant.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › post-infectious disorder › post-viral disorder › post-COVID-19 disorder

Related subtypes (12): oral hairy leukoplakia, Zika virus congenital syndrome, viral dilated cardiomyopathy, hepatitis C induced liver cirrhosis, herpes zoster, hepatitis D virus infection, immunodeficiency 32B, virus associated tumor, rubella encephalitis, AIDS dementia complex, post-infectious neuralgia, AIDS-related disorder

Subtypes (2): multisystem inflammatory syndrome in children and adults, long COVID-19

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 likely risk allele

ClinVar	Variant (HGVS)	Gene	Classification	Review
2628037	NM_001384290.1(HLA-G):c.*65_*66insATTTGTTCATGCCT	HLA-G	Likely risk allele	no assertion criteria provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
HLA-G	HGNC:4964	ENSG00000204632	P17693	HLA class I histocompatibility antigen, alpha chain G	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
HLA-G	HLA class I histocompatibility antigen, alpha chain G	Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	29.2×	0.034

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
HLA-G	Antibody/Immunoglobulin	yes		MHC_I_a_a1/a2, Ig/MHC_CS, Ig_C1-set

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	1
placenta	1
primordial germ cell in gonad	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
HLA-G	124	broad	marker	placenta, primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HLA-G	1,662

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HLA-G	P17693	10

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Endosomal/Vacuolar pathway	1	1038.2×	0.007	HLA-G
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	1	393.8×	0.009	HLA-G
Interferon alpha/beta signaling	1	152.3×	0.011	HLA-G
ER-Phagosome pathway	1	129.8×	0.011	HLA-G
Interferon gamma signaling	1	125.5×	0.011	HLA-G
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	89.2×	0.011	HLA-G
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	87.2×	0.011	HLA-G

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
peripheral B cell tolerance induction	1	16852.0×	0.001	HLA-G
positive regulation of tolerance induction	1	8426.0×	0.001	HLA-G
immune response-inhibiting cell surface receptor signaling pathway	1	5617.3×	0.001	HLA-G
positive regulation of T cell tolerance induction	1	4213.0×	0.001	HLA-G
protection from natural killer cell mediated cytotoxicity	1	2808.7×	0.001	HLA-G
negative regulation of G0 to G1 transition	1	2407.4×	0.001	HLA-G
negative regulation of dendritic cell differentiation	1	2407.4×	0.001	HLA-G
negative regulation of T cell mediated cytotoxicity	1	2106.5×	0.001	HLA-G
positive regulation of natural killer cell cytokine production	1	1872.4×	0.001	HLA-G
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	1	1296.3×	0.002	HLA-G
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	1	1296.3×	0.002	HLA-G
positive regulation of cellular senescence	1	1296.3×	0.002	HLA-G
negative regulation of immune response	1	1053.2×	0.002	HLA-G
protein homotrimerization	1	991.3×	0.002	HLA-G
positive regulation of regulatory T cell differentiation	1	936.2×	0.002	HLA-G
negative regulation of natural killer cell mediated cytotoxicity	1	887.0×	0.002	HLA-G
positive regulation of macrophage cytokine production	1	732.7×	0.002	HLA-G
positive regulation of endothelial cell apoptotic process	1	732.7×	0.002	HLA-G
positive regulation of T cell mediated cytotoxicity	1	510.7×	0.003	HLA-G
positive regulation of interleukin-12 production	1	391.9×	0.003	HLA-G
negative regulation of T cell proliferation	1	330.4×	0.004	HLA-G
cellular defense response	1	318.0×	0.004	HLA-G
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	263.3×	0.004	HLA-G
negative regulation of angiogenesis	1	168.5×	0.006	HLA-G
immune response	1	47.1×	0.021	HLA-G

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
HLA-G	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	HLA-G
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
HLA-G	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.